KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Agilysys (AGYS) Research & Development (2016 - 2025)

Agilysys (AGYS) has disclosed Research & Development for 15 consecutive years, with $18.9 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 26.42% to $18.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $70.8 million through Dec 2025, up 17.63% year-over-year, with the annual reading at $62.4 million for FY2025, 10.0% up from the prior year.
  • Research & Development for Q4 2025 was $18.9 million at Agilysys, up from $17.8 million in the prior quarter.
  • The five-year high for Research & Development was $26.4 million in Q1 2021, with the low at $11.2 million in Q4 2021.
  • Average Research & Development over 5 years is $14.8 million, with a median of $14.4 million recorded in 2023.
  • The sharpest move saw Research & Development soared 183.26% in 2021, then crashed 53.65% in 2022.
  • Over 5 years, Research & Development stood at $11.2 million in 2021, then increased by 10.76% to $12.4 million in 2022, then rose by 17.2% to $14.6 million in 2023, then increased by 2.89% to $15.0 million in 2024, then increased by 26.42% to $18.9 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $18.9 million, $17.8 million, and $17.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.